U.S. Multiple Sclerosis Market: Most Extreme Pricing Abuse

U.S. Multiple Sclerosis (MS) Market:

• Uniform massive U.S. brand price increases in the U.S. MS category from $15,000 to $100,000 per patient/year since Medicare Part D
• Massive U.S. MS drug price increases despite severe competition and many new similar brand and generic drugs reaching the U.S. market over the past decade-plus
  • 2005: 4 similar U.S. MS drugs - each cost about $15,000/patient/year
  • 2019: more than a dozen similar U.S. MS drugs - most now cost more than $100,000 patient/year
  • Link to Whistleblower table of  massive uniform U.S. MS drug price increases
• MASSIVE PRICE INCREASES FOR "OLD" U.S. MS BRAND DRUGS DESPITE PLUMMETING USE AND MARKET SHARE
  • Not possible in a legitimate U.S competitive marketplace
  • Massive "old"' brand increases fueled more pricing abuse with numerous similar new U.S. MS brand drugs reaching the market

• Severe MS brand drug pricing abuse only for Americans
  • Competition prevented virtually all MS price increases outside the U.S. over the past decade-plus
  • Link to Whistleblower chart of U.S. vs. European MS prices

• More than $60 billion in abusive U.S. MS drug costs over the past decade-plus for the eight (8) whistleblower case brand drugs

• More than $4 billion in abusive "pharma fees" paid to the four dominant health insurer/PBMs just for these 8 MS brand drugs
  • Link to to summary of U.S. sales and "pharma fee" financial abuse from the District of Rhode Island (D-RI) Whistleblower case

Specific U.S. MS Brand Drugs:

Biogen’s Avonex (on U.S. market since 1996)

• 2005 Reported U.S. Sales: $939 million
• 2017 Reported U.S. Sales: $1.9 billion
• U.S. Clinical Use/Prescriptions DOWN 60-70% since 2005
• 2017 U.S. Sales WITHOUT Price Increases: $322 million
• 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
• 2018 U.S. “List”/“Sticker” Price: $98,000/patient/year
• Cumulative harm since start of Part D: $12.5+ billion
  • Link to Avonex’s Whistleblower cumulative harm chart 

Teva’s Copaxone (on U.S. market since 1996)

• 2005 Reported U.S. Sales: $782 million
• 2017 Reported U.S. Sales: $3.0 billion
• U.S. Clinical Use/Prescriptions DOWN -40-50% since 2005
• 2017 U.S. Sales WITHOUT Price Increases: $530 million
• 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
• 2018 U.S. “List”/“Sticker” Price: $90-100,000/patient/year
• Cumulative harm since start of Part D: $20 billion
  • Link to Copaxone’s Whistleblower cumulative harm chart   

Pfizer/EMD Serono's Rebif (on U.S. market since 2002)

• 2005 Reported U.S. Sales: $390 million
• 2017 Reported U.S. Sales: $1.26 billion
• U.S. Clinical Use/Prescriptions DOWN -45% since 2005
• 2017 U.S. Sales WITHOUT Price Increases: $216 million
• 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
• 2018 U.S. “List”/“Sticker” Price: $99,000/patient/year
• Cumulative harm since start of Part D: $8.4 billion
  • Link to Rebif's Whistleblower cumulative harm chart   

Bayer's Betaseron (on U.S. market since 1993)

• 2005 Reported U.S. Sales: $584 million
• 2017 Reported U.S. Sales: $482 million
• U.S. Clinical Use/Prescriptions DOWN -80% since 2005
• 2017 U.S. Sales WITHOUT Price Increases: $77 million
• 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
• 2018 U.S. “List”/“Sticker” Price: $103,000/patient/year
• Cumulative harm since start of Part D: $4.6 billion
  • Link to Betaseron’s Whistleblower cumulative harm chart